1. Home /
  2. Pharmaceuticals

Pharmaceuticals

Gilead Sciences Names Roche's O'Day as CEO and Chairman

Gilead Sciences Names Roche's O'Day as CEO and Chairman

Daniel O'Day will take over the helm of the biopharmaceutical giant on March 1, 2019.

Abbott, Glaxo, Casella and More: 'Mad Money' Lightning Round

Abbott, Glaxo, Casella and More: 'Mad Money' Lightning Round

Jim Cramer weighs in on Abbott, GlaxoSmithKline, Waste Management and more.

CVS Health to Roll Out New Drug Pricing Model

CVS Health to Roll Out New Drug Pricing Model

The new model will allow CVS Caremark to pass through 100% of drug rebates to its health plan clients.

Pfizer Is in Breakout-Mode This Fall: Chart

Pfizer Is in Breakout-Mode This Fall: Chart

This healthcare stock looks healthy for your portfolio amid the volatility.

Bristol-Myers Drops After Lung-Cancer Drug Study Fails

Bristol-Myers Drops After Lung-Cancer Drug Study Fails

Shares decline after the company says a lung-cancer study it had been working on failed.

Tech Selloff Could Work in Favor of Pharmaceutical Stocks

Tech Selloff Could Work in Favor of Pharmaceutical Stocks

Pharma could be the best parking spot for your money if the market keeps trending downward.

Pfizer Shares Rise Even as U.S. Lawmakers, Administration Criticize Drug Pricing

Pfizer Shares Rise Even as U.S. Lawmakers, Administration Criticize Drug Pricing

Shares of the New York City-based pharmaceutical giant are rising on Monday.

Pfizer's Oncology Offerings Present Opportunity for Long-Term Stock Growth

Pfizer's Oncology Offerings Present Opportunity for Long-Term Stock Growth

The cancer drug market is expected to grow from a surveyed total value of $78 billion in 2015 to over $110 billion by 2020.

Jim Cramer Reacts to Pfizer's Drug Hikes

Jim Cramer Reacts to Pfizer's Drug Hikes

Jim Cramer responds to the news that the drug company, Pfizer, has hiked rates.

Here's a Handful of Ways to Navigate Biotech's Choppy Seas

Here's a Handful of Ways to Navigate Biotech's Choppy Seas

Biotech ETFs could mitigate risk amid the sector's volatility, and names such as Exelixis, ANI Pharmaceuticals and Progenics hold promise.